Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

Samsung Bioepis’ ustekinumab biosimilar receives Japanese marketing approval: Incheon, Korea Wednesday, December 24, 2025, 15:00 Hrs [IST] Samsung Bioepis Co., Ltd., a biopharma ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...

A clandestine clinic, set up inside a private residence by a self-proclaimed doctor where cosmetic procedures were performed, was discovered in Capua by the financial police of the ...

Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

While the expanded approval fulfills an unmet meet in postmenopausal women, its benefits are marginal in that population.